45 results about "Antithrombins" patented technology

The invention discloses a processing method of traditional Chinese medicinal material poecilobdella manillensis, and belongs to the technical field of traditional Chinese medicines. The processing method disclosed by the invention comprises the following steps: (1) carrying out feed deprivation culture on living poecilobdella manillensis; (2) freezing the living poecilobdella manillensis after the feed deprivation culture is finished; (3) performing water bath ultrasonic treatment on the frozen poecilobdella manillensis; the frequency of ultrasonic waves during ultrasonic treatment is 20-40 kHz; and (4) freeze-drying the poecilobdella manillensis subjected to the water bath ultrasonic treatment, and crushing to obtain the poecilobdella manillensis freeze-dried powder The processing method provided by the invention effectively solves the problem that the activity of antithrombin is reduced due to high temperature, reduces the fishy smell caused by blood storage in the body of the poecilobdella manillensis, improves the efficacy and quality of the poecilobdella manillensis freeze-dried powder, and improves the acceptance of patients. The processing process is low in energy consumption, easy in production condition control, high in processing efficiency and suitable for popularization and application.

The invention discloses a group of pyemia specific biomarkers and application thereof, and belongs to the field of medical detection.The biomarkers are formed by combination of alpha 1-microglobulin / Bikunin precursor protein and one or more of antithrombin III protein, apolipoprotein A1 or apolipoprotein H, according to the invention, seven core proteins, namely APOA1, APOH, AMBP, SERPINC1, F2, FGG and FGB, are screened from TMT proteomics of serum of a clinical hemorrhagic patient, and four more important proteins, namely APOA1, APOH, AMBP, SERPINC1, F2, FGG and FGB, are obtained by further screening the seven proteins in a hemorrhagic cell model and the clinical hemorrhagic patient. The four proteins are verified again in serum of a hemorrhagic mouse animal experiment and an expanded-scale clinical hemorrhagic patient, and the potential of the four core proteins as serum biomarkers for early diagnosis of hemorrhagic disease is determined.

The present invention relates to the use of Antithrombin in the treatment of stroke.

The application discloses a method for preparing and removing odor of Hirudo nipponia freeze-dried powder, and the method comprises the following steps: inducing clean treatment in an empty stomach, low-temperature stress pretreatment, in-situ quick freezing under the protection of inert gas, segmented vacuum freeze-drying and low-temperature airflow crushing. The application induces the expression up-regulation of aldehyde dehydrogenase and alcohol dehydrogenase in the body of Hirudo nipponia through low-temperature stress, and utilizes ice crystals to destroy cell compartmentalization in in-situ quick freezing, so that the enzymes and their substrates are contacted, in-situ enzymatic conversion occurs under the protection of inert gas, and fishy components are degraded into low-smell metabolites. The application does not need exogenous odor-removing substances and post-processing procedures, has high antithrombin activity retention rate, greatly reduces the total amount of fishy substances, and realizes in-situ synergistic odor removal in the whole freeze-drying process.

The present application relates to the technical field of biological medicine, and provides a thrombin-antithrombin III complex antibody, a detection kit and application thereof.The present application specifically discloses a thrombin monoclonal antibody and an antithrombin III monoclonal antibody pairing combination, an intermediate product and a detection kit product containing the same.The antibody combination of the present application can be combined with the thrombin-antithrombin III complex in a double-antibody sandwich method with high sensitivity and strong specificity;the thrombin-antithrombin III complex detection kit suitable for the immunochemiluminescence method is prepared by using the above antibody, and the thrombin-antithrombin III complex in the human body can be detected by a two-step method.

This invention relates to the field of antibodies, and more particularly to TAT antibodies and their applications. The invention provides coated antibodies comprising a heavy chain variable region and a light chain variable region, wherein: the CDR1, CDR2, and CDR3 regions of the heavy chain variable region have amino acid sequences as shown in SEQ ID No:1 to SEQ ID No:3; and the CDR1, CDR2, and CDR3 regions of the light chain variable region have amino acid sequences as shown in SEQ ID No:4 to SEQ ID No:6. This invention successfully prepared highly specific monoclonal antibodies 7E10 and 2B4 against the thrombin-antithrombin III complex (TAT), wherein 7E10 specifically binds to thrombin (THR), and 2B4 specifically binds to antithrombin III (AT-III). Using these two antibodies in combination enables highly sensitive and specific detection of the TAT complex.

There has been demand for a pharmaceutical composition containing blood coagulation factor X in which the amount of FXa is suppressed. Provided is a pharmaceutical composition containing blood coagulation factor X, the pharmaceutical composition furthermore containing antithrombin III.

The present invention discloses a gene therapy for hereditary antithrombin deficiency based on AAV, belonging to the field of gene therapy technology. The present invention explores for the first time the long-term effect and safety of hSERPINC1 gene delivery mediated by AAV vector in the treatment of hereditary AT deficiency, and proves its efficacy in restoring the AT antigen level and activity in the plasma of AT-deficient mice, rebalancing the coagulation and anticoagulation systems in the body, and reducing the thrombosis tendency of mice. AAV gene therapy is expected to completely cure AT deficiency. This discovery provides a preclinical basis for the clinical transformation of AAV therapy for the treatment of AT deficiency, and provides a new treatment direction for the long-term radical cure of patients with thrombophilias such as hereditary antithrombin deficiency.

The invention pertains to a therapeutic formulation, CARDIOGARDIA, for the management of cardiac arrest. The formulation co-formulates selected microRNAs, including miR-21, miR-1, miR-29, miR-17, and miR-133, and antithrombin and essential electrolytes in a single formulation. The different components in combination target various pathological processes associated with cardiac arrest, including fibrosis, apoptosis, arrhythmia, and coagulopathy. Delivery may be affected by suitable pharmaceutical vehicles or carriers to enable effective delivery. By acting on these distinct pathological processes in combination, the formulation provides a multifaceted approach to stabilizing cardiac function and improving resuscitation outcome. The invention further encompasses methods of treating subjects experiencing cardiac arrest by administering the formulation in therapeutically effective amounts.

The present invention relates to an anticoagulant heparin-derived oligosaccharide biphenyl dimer, and a preparation method therefor and a use thereof. The anticoagulant heparin-derived oligosaccharide biphenyl dimer has a structure as represented by general formula I, and a benzene ring can be replaced with substituted phenyl, an aromatic heterocyclic ring or a substituted aromatic heterocyclic ring. The heparin-derived oligosaccharide biphenyl dimer of the present invention has few synthesis steps and a significantly high overall yield, has antithrombin-dependent potent and specific anti-Xa factor activity and no obvious anti-IIa activity, anticoagulant activity being efficiently neutralized by a protamine, and has excellent pharmacokinetics characteristics. Therefore, the present invention is suitable for preparing novel anticoagulant and antithrombotic drugs having cost advantages, and high quality and safety.

Various embodiments of the invention utilize chalcones to treat blood, bleeding, and / or bleeding disorders. As described herein, chalcones significantly reduce blood clotting time in normal / hemophilic blood and normal / hemophilic animal models. As also described herein, chalcones reduce blood clotting time and increase blood clotting efficiency without any apparent risk of immunogenicity or unwanted blood clots. As also described herein, chalcones reduce the inhibitory activity of antithrombin on thrombin-driven blood clotting, thereby increasing the effectiveness of the thrombin mechanism in clotting blood.

The invention provides a method for improving the appearance of a freeze-dried antithrombin III product. The method comprises the following steps: carrying out pre-freezing treatment and sublimation drying treatment on a sample containing antithrombin III; the pre-freezing treatment comprises at least two cooling steps, and the temperature of each cooling step is-60 to-20 DEG C independently; the sublimation drying treatment comprises at least three heating steps, and the temperature of each heating step is-45 DEG C to 0 DEG C independently. The antithrombin III freeze-dried product obtained by the method disclosed by the invention meets the requirements of pharmacopoeia quality standards, and has the advantages of good molding, full appearance, no shrinkage, no collapse, no compact film layer at the top, high mechanical strength, good product stability and high market value, and is beneficial to storage and transportation.

The invention relates to the technical field of biological medicine, and provides a thrombin-antithrombin III compound antibody, a detection kit and application of the thrombin-antithrombin III compound antibody. The invention specifically discloses a pairing combination of a thrombin monoclonal antibody and an antithrombin III monoclonal antibody, an intermediate product, a detection reagent product containing the pairing combination and the intermediate product, and the like. The antibody combination disclosed by the invention can be combined with a thrombin-antithrombin III compound with high sensitivity and strong specificity by a double-antibody sandwich method; a thrombin-antithrombin III compound detection kit suitable for an immunochemiluminescence method is prepared by using the antibody, and the thrombin-antithrombin III compound in a human body can be detected by a two-step method.

The application relates to the technical field of biological medicine, and particularly discloses a kit for determining antithrombin III activity, which comprises a first reagent, a second reagent, a third reagent and a diluent; the first reagent at least comprises a first buffer, thrombin, a serine protease inhibitor and a first stabilizer; the second reagent at least comprises a second buffer, a chromogenic substrate and a second stabilizer; the third reagent at least comprises a third buffer, heparin, isopropyl alcohol and a third stabilizer; and the diluent at least comprises physiological saline and a fourth stabilizer. In the kit, the cost is low, the anti-interference capability is strong, the sensitivity is high, the stability is good, and the kit has a wide application prospect.

The invention discloses an antithrombin III determination kit and an application thereof. The kit is composed of the following components: a reagent R1 is a buffer solution component and comprises a buffer solution, sodium chloride, propyl alcohol, BSA and a preservative; the reagent R2 is a chromogenic substrate component and comprises a heparin-AT compound, thrombin, a specific chromogenic substrate S-2238, a novel stable peptide A, a stabilizer and a standard substance. The stable peptide A is innovatively adopted to improve the stability of the reagent, and the AT-III activity in the plasma is indirectly quantified by measuring the hydrolysis reaction absorbance change of the specific chromophoric substrate S-2238 at the wavelength of 405 nm. The kit has the remarkable technical effects that the reagent stability is excellent, the detection specificity is high, the anti-interference capability is strong, the operation is convenient, the linear range is wide (0.5-12 IU / ml), the sensitivity is improved by 30% compared with the prior art, and the clinical conventional detection requirements can be met.

The invention provides an antithrombin III determination kit, and belongs to the technical field of in-vitro detection.The kit comprises a reagent R1 and a reagent R2, the reagent R1 comprises thrombin, benzamidine hydrochloride, hypericin and a reaction regulator, the reaction regulator is glycine and at least one of potassium chloride, sodium chloride, potassium sulfate and ammonium sulfate, and the reagent R2 comprises a reagent R1 and a reagent R2. The reagent R2 comprises a chromophoric substrate. In the kit disclosed by the invention, instantaneous inhibition of benzamidine hydrochloride added into the reagent R1 on thrombin and long-acting stabilization of hypericin are complementary, so that the stability of the reagent can be effectively improved, and meanwhile, the kit has good accuracy and repeatability and a relatively wide linear range; a new idea is provided for solving the stability problem of an antithrombin III activity detection reagent based on a chromophoric substrate method.

Various embodiments of the invention utilize flavanones, including, but not limited to, 3-hydroxyflavone compounds and 3-hydroxyflavone sugar compounds, to treat blood, bleeding, and / or bleeding disorders. As described herein, flavanones significantly reduce blood clotting time in normal / hemophilic blood and normal / hemophilic animal models. As also described herein, flavanones reduced blood clotting time and increased clotting efficiency in blood without any apparent risk of immunogenicity or risk of unwanted blood clots. As also described herein, flavanones reduce the inhibitory activity of antithrombin on thrombin-driven blood clotting, thereby increasing the effectiveness of the thrombin mechanism in clotting blood.

The application discloses an anti-heparin-antithrombin complex antibody and application thereof in a heparin drug anticoagulation effect detection method, and comprises an antibody molecule capable of combining with a heparin-antithrombin complex, a light chain variable region amino acid sequence of the antibody molecule is shown as SEQ ID NO:1, and a heavy chain variable region amino acid sequence is shown as SEQ ID NO:2. The antibody molecule can be prepared into a kit for detecting the anticoagulation effect of the heparin drug, and has the characteristics of simple operation, high sensitivity, good repeatability, wide linearity and the like, and is suitable for high-throughput testing of the anticoagulation effect of the heparin drug.

The invention provides a poecilobdella manillensis breeding feed and a preparation method thereof, and relates to the technical field of aquaculture. The poecilobdella manillensis breeding feed comprises the following components: animal blood freeze-dried powder, soybean meal, phenylalanine, isoleucine, aspartic acid, mannan oligosaccharide, a traditional Chinese medicine extract, syringin, magnesium lignosulfonate, vitamins and fishy flavor essence. According to the feed for feeding poecilobdella manillensis, by optimizing the components, the proportion and the preparation method, the survival rate, the body weight growth rate and the antithrombin activity growth rate of the poecilobdella manillensis are remarkably increased, and the prevalence rate of the poecilobdella manillensis is reduced.

The invention provides application of a blood coagulation four-item detection reagent, a plasma D dimer detection reagent and an AT-III detection reagent in preparation of a diabetic microangiopathy detection kit and the kit, and relates to the technical field of medical biology. The research finds that the microangiopathy of the T2DM patient is obviously associated with the four blood coagulation items, the plasma D dimer and the AT-III level, and the four blood coagulation items, the plasma D dimer and the AT-III all cause independent influence factors of the microangiopathy, so that the risk of the microangiopathy of the T2DM patient can be predicted by detecting related indexes clinically; the clinical auxiliary diagnosis value is relatively high; further, prothrombin time detection results, activated partial thromboplastin time detection results, thrombin time detection results and fibrinogen detection results can be obtained on the basis of a four-item blood coagulation detection reagent, a plasma D dimer detection reagent and an AT-III detection reagent; determining the risk of the diabetic microangiopathy according to at least one of a blood plasma D dimer detection result and an antithrombin III detection result.

The invention relates to an anti-prothrombin / phosphatidylserine antibody, a pharmaceutical composition and an application of the anti-prothrombin / phosphatidylserine antibody. The anti-prothrombin / phosphatidylserine antibody provided by the invention is connected with a prothrombin / phosphatidylserine compound with high affinity, so that the antibody is combined with phosphatidylserine in a targeted manner to achieve the treatment of tumor resistance, infection resistance, thrombosis resistance, atherosclerosis, ischemia-reperfusion injury, inflammatory bowel disease, Alzheimer's disease and Parkinson's disease.

The invention discloses an application of Spy Tag / Spy Catcher in preparation of a thrombin-antithrombin III compound, a preparation method of the thrombin-antithrombin III compound and an application of the thrombin-antithrombin III compound. The preparation method comprises the following steps: respectively obtaining a Spy Catcher-Thrombin gene segment and a Spy Tag-Antithrombin gene segment; respectively connecting the gene segments to starting vectors to form corresponding connectors; carrying out conversion and screening operation on the linker to obtain a corresponding recombinant plasmid; carrying out transformation and induction operation on the recombinant plasmid, so as to obtain a Spy Catcher-Thrombin recombinant protein and a Spy Tag-Antithrombin recombinant protein; the preparation method comprises the following steps: mixing the Spy Catcher-Thrombin recombinant protein with the Spy Tag-Antithrombin recombinant protein, and carrying out a reaction, so as to obtain the TAT protein. According to the method, the spontaneous reaction of Spy Tag / Spy Catcher is utilized, other chemical cross-linking agents are not needed, the cost can be reduced, green production is facilitated, and the recombinant protein can be produced on a large scale by utilizing a cell culture technology; the recombinant TAT antigen and the recombinant TAT antibody prepared by the invention have strong immunoreactivity, and completely meet the requirements of thrombus detection on the TAT antigen.

The present disclosure provides methods and systems for modeling, simulating, and treating hemophilia. The methods and systems disclosed herein include a quantitative systems pharmacology (QSP) model for predicting thrombin generation characteristics in people with hemophilia A and people with hemophilia B in relation to antithrombin (AT) decline.

Compounds and compositions for determining the level of antithrombin (ATIII) in a sample are described. Methods of forming the compounds and compositions are also described. Methods of using the compounds and compositions to quantify the level of ATIII in a subject are further described. The methods can be used to facilitate determining a dosage or heparin or ATIII to administer to a patient.

The invention discloses a traditional Chinese medicine composition for tonifying kidney, nourishing blood and preventing miscarriage as well as a preparation method, a detection method and application thereof, and belongs to the technical field of traditional Chinese medicine, the traditional Chinese medicine composition comprises the following medicine raw materials in parts by weight: 450-550 parts of semen cuscutae, 400-430 parts of Chinese yam, 400-430 parts of angelica sinensis, 400-430 parts of parasitic loranthus, 400-430 parts of teasel root, 400-430 parts of radix paeoniae alba, 400-430 parts of fructus nelumbinis and 230-260 parts of radix aucklandiae. Experimental studies show that the composition can specifically regulate expression levels of thrombosis-related factors (TF, PAI-1 and antithrombin III AT-III) and inflammatory factors (IL-6) in trophoblast cells and vascular endothelial cells, so that placenta local abnormal thrombosis is inhibited, maternal-fetal interface immune inflammation reaction is improved, and recurrent abortion is effectively prevented and treated.

The invention belongs to the technical field of immunodetection analysis, and discloses a kit for quantitative detection of a thrombin-antithrombin III compound and a preparation method of the kit. The kit comprises a magnetic bead working solution, an acridinium ester marker working solution, a biotin marker working solution, a TAT calibrator and a TAT quality control product, and quantitative detection of TAT is realized by combining a double-antibody sandwich method with a chemiluminescence technology. The method overcomes the defects that an existing fluorescence immunoassay method is low in repeatability, and an immunoturbidimetry method is high in requirement for specimens and limited in low-concentration detection capacity, and has the advantages of being high in specificity, sensitivity and accuracy and easy, convenient and rapid to operate. The method can be used for clinical auxiliary diagnosis of thrombogenic diseases such as disseminated intravascular coagulation (DIC) and venous thromboembolism (VTE), and provides a basis for blood coagulation state evaluation and clinical decision making.

Various embodiments of the invention utilize chalcones to treat blood, bleeding, and / or bleeding disorders. As described herein, chalcones significantly reduce blood clotting time in normal / hemophilic blood and normal / hemophilic animal models. As also described herein, chalcones reduce blood clotting time and increase blood clotting efficiency without any apparent risk of immunogenicity or unwanted blood clots. As also described herein, chalcones reduce the inhibitory activity of antithrombin on thrombin-driven blood clotting, thereby increasing the effectiveness of the thrombin mechanism in clotting blood.

The invention relates to the field of biological medicine, in particular to an antithrombin III determination kit and a preparation method thereof. The antithrombin III determination kit comprises a reagent 1, a reagent 2, an ATIII calibration product and an ATIII quality control product. The reagent 1 is prepared from a Tris-HCl buffer solution, calcium chloride, bovine serum albumin, potassium ferrocyanide, gentamicin sulfate, ProClin 300, recombinant human thrombin and a nano blocking agent; the reagent 2 is prepared from a Tris-HCl buffer solution, S-2238, gentamicin sulfate and ProClin 300; the ATIII calibrator is prepared from a synthetic plasma matrix, recombinant human ATIII, natural ATIII, ProClin 300, a blood coagulation inhibitor, protamine and trehalose; the ATIII quality control product is prepared from a synthetic plasma matrix, recombinant human ATIII, natural ATIII, ProClin 300, a blood coagulation inhibitor, trehalose and mannitol, according to the scheme, the method is suitable for a full-automatic blood coagulation analysis platform and conforms to the development trend of in-vitro diagnostic reagents.

The present invention relates to the use of antithrombin in the treatment of stroke.

Provided in the present invention is an anti-prothrombin / phosphatidylserine antibody, comprising a heavy chain variable region and a light chain variable region; the heavy chain variable region comprises HCDR1 to HCDR3 having amino acid sequences as shown in SEQ ID NOs: 1-3, respectively, and the light chain variable region comprises LCDR1 to LCDR3 having amino acid sequences as shown in SEQ ID NOs: 4-6, respectively. The anti-prothrombin / phosphatidylserine antibody of the present invention can bind to a prothrombin / phosphatidylserine complex with high affinity, thereby targeting and binding to phosphatidylserine, and has a potential therapeutic effect with respect to tumors, infections, atherosclerosis, ischemia-reperfusion injury, inflammatory bowel disease, Alzheimer's disease, Parkinson's disease, etc.